<DOC>
	<DOCNO>NCT00003955</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy combine radiation therapy treat patient metastatic rhabdomyosarcoma sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Metastatic Rhabdomyosarcoma Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient newly diagnose high-risk metastatic stage IV/clinical group IV rhabdomyosarcoma treat upfront window therapy comprise irinotecan vincristine . - Determine toxic effect regimen patient . - Determine toxic effect regimen give alternate course vincristine , dactinomycin , cyclophosphamide ( VAC ) continuation therapy patient partial complete response . - Determine overall failure-free survival patient treat irinotecan vincristine follow VAC alone VAC alternate vincristine irinotecan plus radiotherapy . - Determine pharmacokinetics irinotecan vincristine patient . OUTLINE : - Upfront window therapy : Patients receive vincristine IV day 1 8 irinotecan IV 60 minute day 1-5 8-12 . Treatment repeat every 21 day total 2 course . Patients experience partial complete response proceed regimen A . Patients experience stable progressive disease proceed regimen B . - Regimen A : Patients receive vincristine IV 1 minute weekly week 6-13 , 15-19 , 23-27 , 29 , 32-35 , 38-39 , 41 ; dactinomycin IV 1 minute weekly week 6 , 12 , 23 , 29 , 35 , 41 ; cyclophosphamide IV 30-60 minute weekly week 6 , 12 , 16 , 19 , 23 , 29 , 35 , 41 . Patients also receive irinotecan IV 1 hour daily , 5 day week , week 9 , 10 , 26 , 27 , 32 , 33 , 38 , 39 undergo radiotherapy daily , 5 day week , week 15-22 . - Regimen B : Patients receive vincristine regimen A ; dactinomycin IV 1 minute weekly week 6 , 9 , 12 , 23 , 26 , 29 , 32 , 35 , 38 , 41 cyclophosphamide IV 30-60 minute weekly week 6 , 9 , 12 , 16 , 19 , 23 , 26 , 29 , 32 , 35 , 38 , 41 . Patients receive radiotherapy regimen A . Patients receive upfront window irinotecan/vincristine therapy treat standard therapy . - Standard therapy : Patients receive vincristine IV 1 minute weekly week 0-13 , 15-19 , 23-27 , 29 , 32-35 , 38 , 41 ; dactinomycin IV 1 minute weekly week 0 , 6 , 9 , 12 , 23 , 26 , 29 , 32 , 35 , 38 , 41 ; cyclophosphamide IV 30-60 minute weekly week 0 , 3 , 6 , 9 , 12 , 16 , 19 , 23 , 26 , 29 , 32 , 35 , 38 , 41 . Patients without evidence intracranial extension receive radiotherapy daily , 5 day week , week 15-22 . Patients evidence intracranial extension , require emergency radiotherapy , receive radiotherapy week 0-6 . Dactinomycin withhold radiotherapy . All patient receive filgrastim ( G-CSF ) sargramostim ( GM-CSF ) subcutaneously ( SC ) begin 24 hour completion course chemotherapy continue blood count recover . Alternatively , patient may receive pegfilgrastim SC begin 24-36 hour completion course chemotherapy continue blood count recover . Patients follow every 2 month 1 year , every 4 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 18-46 patient accrue study within 9-24 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic stage IV/clinical group IV rhabdomyosarcoma , undifferentiated sarcoma , ectomesenchymoma No metastatic embryonal tumor patient 10 year age , regardless primary site Metastatic tumor parameningeal site eligible Bidimensionally measurable disease No positive cerebrospinal fluid cytology multiple intracranial metastasis Patients present follow eligible continuation therapy may receive irinotecan/vincristine upfront window therapy : Evidence base skull erosion skull metastatic disease displaces indent dura , compress brain parenchyma , cause evidence cranial nerve palsy Tumor touch displace spinal cord Evidence intracranial primary tumor extension Tumors could cause potentially lifethreatening complication ( e.g. , renal , airway ) progression due location and/or growth rate Requires emergency radiotherapy Lab value consistent disseminate intravascular coagulation PATIENT CHARACTERISTICS : Age : Under 50 ( alveolar rhabdomyosarcoma , undifferentiated sarcoma , ectomesenchymoma patient ) 10 49 ( embryonal histology patient ) Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute neutrophil count great 1,000/mm^3* Platelet count great 150,000/mm^3* NOTE : *Unless tumor involvement bone marrow Hepatic : Bilirubin le 1.5 mg/dL PT , PTT , fibrinogen le 1.5 time upper limit normal Renal : Creatinine le 1.2 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior steroid allow Radiotherapy : See Disease Characteristics No prior radiotherapy Surgery : No 42 day since prior initial surgical procedure , include biopsy diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>childhood malignant mesenchymoma</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>